Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Eli Lilly's $3 billion investment in manufacturing capacity for tirzepatide is in the spotlight as compounding pharmacies challenge an FDA decision to end the drug shortage. Meanwhile, Amgen is making waves with a $1 billion investment, adding 370 jobs in North Carolina and potentially ramping up manufacturing for an obesity drug. In other news, Protara and CG Oncology are excited to share promising outcomes for bladder cancer treatments. The FDA has also outlined guidelines for accelerated reviews, aiming to clarify expectations after recent controversies. Additionally, Novo is making significant manufacturing investments, and the Trump administration's impact on biopharma continues to be a topic of discussion. Job opportunities in the industry are also something to keep an eye on.